CONMED Corporation reports news on its medical technology business, which provides surgical devices and equipment used by surgeons and other healthcare professionals across multiple specialties. Company updates commonly cover sales trends, domestic and international revenue, GAAP and adjusted earnings, full-year outlooks, and management presentations in the healthcare sector.
Recurring announcements also address portfolio optimization, including the exit or reduction of certain gastroenterology products, and the company’s focus on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. Other corporate news includes finance leadership changes and operating initiatives tied to supply chain execution, product rationalization, and margin profile.
CONMED Corporation (NYSE: CNMD) announced a change in its presentation time at the Jefferies Virtual London Healthcare Conference to 11:25 a.m. ET on November 18, 2020. Todd W. Garner, Executive Vice President and CFO, will represent the company. The presentation will be available via a live webcast on the company's website, with a replay accessible afterward.
CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties, including orthopedics, general surgery, and more. For further details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) announced that Todd W. Garner, Executive Vice President and CFO, will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 12:25 p.m. ET. A live webcast of the presentation will be available in the ‘Investors’ section on the company’s website, with a replay accessible post-event. CONMED specializes in medical technology, providing surgical devices for minimally invasive procedures across various specialties including orthopedics and neurosurgery. For further details, visit www.conmed.com.
CONMED Corporation (NYSE: CNMD) reported Q3 2020 financial results with sales of $237.8 million, an increase of 1.8% year-over-year. Domestic revenues grew by 4.7%, while international revenues fell by 1.7%. GAAP diluted EPS was $0.23, unchanged from Q3 2019, but adjusted diluted EPS rose to $0.88 from $0.62. The company noted ongoing operational challenges due to COVID-19 but expressed confidence in achieving future growth. However, financial guidance remains unavailable due to pandemic uncertainties.
CONMED Corporation (NYSE: CNMD) will report its financial results for Q3 2020 after market close on October 28, 2020. A conference call will be held at 4:30 p.m. ET for discussions regarding the results. Interested parties can access the call by dialing 1-844-889-7792 (domestic) or +1-661-378-9936 (international) using passcode 2498889. The call will also be webcast on the company’s website. Forward-looking statements will be included, highlighting potential risks and uncertainties affecting future performance.